Loading stock data…
$10.26+0.14 (+1.38%)
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Puma Biotechnology, Inc. in the Healthcare sector is trading at $10.26 with a market capitalization of $538M. The stock is currently near its 52-week high of $10.50, remaining 34.3% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $56.50M↑ | $44.81M↓ | $75.45M↑ | $54.48M↑ | $52.44M |
| Gross Profit | $44.03M↑ | $34.39M↓ | $52.33M↑ | $42.30M↑ | $40.13M |
| Operating Income | $7.58M↑ | -$3.83M↓ | $17.11M↑ | $9.57M↑ | $6.64M |
| Net Income | $8.19M↑ | -$3.75M↓ | $13.44M↑ | $8.84M↑ | $5.86M |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat...